Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (231-240 of 770) with videos related to

Pageof 77
Sort By:
American Heart Journal|March 27, 2007
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical centerAslan T Turer, Kenneth W Mahaffey, Kate L Compton, et al.
JACC. Heart Failure|December 31, 2016
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug DevelopmentNorman Stockbridge, Kristen Miller, Shashi Amur, et al.
American Heart Journal|August 17, 2004
Slowing the progression of diabetic nephropathy and its cardiovascular consequencesPeter A McCullough, George L Bakris, William F Owen, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 4, 2012
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort studyJohn J V McMurray, Robert M Califf, Angelyn M Bethel, et al.
Expert Opinion on Investigational Drugs|May 22, 2008
Rivaroxaban, an oral direct factor Xa inhibitorJonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, et al.
The American Journal of Medicine|January 13, 2004
Economic effects of beta-blocker therapy in patients with heart failurePatricia A Cowper, Elizabeth R DeLong, David J Whellan, et al.
Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.
JAMA Network Open|October 8, 2020
Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical TrialsFan Wang, Richard L Schilsky, David Page, et al.
American Heart Journal|June 6, 2020
Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelinesAlexander C Fanaroff, Marat Fudim, Robert M Califf, et al.
American Heart Journal|November 5, 2003
Evaluation of the dofetilide risk-management programNancy M Allen LaPointe, Anita Chen, Bradley Hammill, et al.
Pageof 77

Showing results (231-240 of 770) with videos related to

Sort By:
Pageof 77
American Heart Journal|March 27, 2007
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical centerAslan T Turer, Kenneth W Mahaffey, Kate L Compton, et al.
JACC. Heart Failure|December 31, 2016
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug DevelopmentNorman Stockbridge, Kristen Miller, Shashi Amur, et al.
American Heart Journal|August 17, 2004
Slowing the progression of diabetic nephropathy and its cardiovascular consequencesPeter A McCullough, George L Bakris, William F Owen, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 4, 2012
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort studyJohn J V McMurray, Robert M Califf, Angelyn M Bethel, et al.
Expert Opinion on Investigational Drugs|May 22, 2008
Rivaroxaban, an oral direct factor Xa inhibitorJonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, et al.
The American Journal of Medicine|January 13, 2004
Economic effects of beta-blocker therapy in patients with heart failurePatricia A Cowper, Elizabeth R DeLong, David J Whellan, et al.
Journal of Interventional Cardiology|February 6, 2013
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?Peter B Berger, Judson B Williams, Vic Hasselblad, et al.
JAMA Network Open|October 8, 2020
Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical TrialsFan Wang, Richard L Schilsky, David Page, et al.
American Heart Journal|June 6, 2020
Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelinesAlexander C Fanaroff, Marat Fudim, Robert M Califf, et al.
American Heart Journal|November 5, 2003
Evaluation of the dofetilide risk-management programNancy M Allen LaPointe, Anita Chen, Bradley Hammill, et al.
Pageof 77